Celebrating Student Scholarship with an Undergraduate Research Prize

The Leatherby Libraries at Chapman University started its research prize contest for undergraduate students in 2007. Having reached the tenth anniversary of the contest, we are well positioned to reflect on how the contest has changed in concert with new ways of inquiry and information creation and on its role in supporting and honoring student research. A decade of experience has taught us how to diversify the contest and reflect collectively on its merits. In this chapter, we present a case study of how the Kevin and Tam Ross Undergraduate Research Prize (URP) recognizes and honors student scholarship. We explain the goals and processes of the contest and discuss the partnership elements that make the URP contest successful. A student contestant and a contest benefactor coauthor this chapter, enabling a forum with rich and diverse perspectives on the benefits of the competition. The reflection by student Talia Cain, presented in part above, underscores how the process of conducting research has contributed to the development of her scholarly identity.https://digitalcommons.chapman.edu/librarian_books/1004/thumbnail.jp

Yorba Times: Standing Up, Speaking Out

During the Spring 2018 semester, Dr. Noah Asher Golden\u27s Teaching of Writing K-12 students partnered with the Journalism class at Yorba Academy for the Arts. Through collaboration over a four-month period, Chapman\u27s future teachers and Yorba\u27s junior high journalists engaged a deep writing process to write a series of features, editorials, and news articles related to a number of global issues. Thank you to Ms. Andrea Lopez, Ms. Kori Shelton, Mr. Nick Sepulveda, Ms. Tracy Knibb, and the Lloyd E. and Elisabeth H. Klein Family Foundation for supporting this project.https://digitalcommons.chapman.edu/yorba-chapman/1003/thumbnail.jp

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

1st Place Contest Entry: Critical Media Literacy: Liberating the Criminal and Empowering African American Males

This is Talia Cain\u27s submission for the 2017 Kevin and Tam Ross Undergraduate Research Prize, which won first place. She wrote about how media contributes to the criminalization of African American males and the effects of this on African American male students. Talia is a sophomore at Chapman University, majoring in Integrated Educational Studies. Her faculty mentor is Professor Anne Steketee

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

International audienc